SPOTLIGHT: U.S. 'a complete mess,' Indian CEO says

Dr. Reddy's vice chair and CEO G.V. Prasad predicts increasing difficulty obtaining financing and declining market caps industry-wide as the U.S. economy slows. But, he says, India and China will grow as traditional pharma markets brake. "The U.S. is in a complete mess," Prasad told the Indian pub DNA Money in a Q&A interview. Report 

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.